Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interleukin-2 Imaging as a Guide to Cancer Immunotherapy (Ipilimumab or Pembrolizumab) in Advanced Melanoma: A Pilot Study

NCT01789827 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01789827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01789827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interleukin-2 Imaging as a Guide to Cancer Immunotherapy (Ipilimumab or Pembrolizumab) in Advanced Melanoma: A Pilot Study
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2014
Completion date
June 27, 2018
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv skin melanoma